Q2 2024 Bioatla Inc Earnings Call Transcript
Key Points
- BioAtla Inc (BCAB) received a Fast Track designation from the FDA for ozuriftamab vedotin, highlighting its potential in treating refractory head and neck cancer.
- The company reported a manageable safety profile with no new safety signals for its CAB-ROR2-ADC ozuriftamab vedotin.
- BioAtla Inc (BCAB) observed promising clinical benefits in patients with KRAS mutations, including a complete response maintained for over two years.
- The company is on track to meet with the FDA to discuss potentially registrational trials for its CAB-ROR2 and CAB CTLA-4 assets.
- BioAtla Inc (BCAB) is in meaningful discussions regarding potential strategic partnerships, with confidence in establishing collaborations this year.
- Research and development expenses decreased significantly, indicating potential challenges in sustaining the same level of innovation and development.
- Net loss for the quarter was $21.1 million, although reduced from the previous year, it still represents a significant financial challenge.
- Cash and cash equivalents decreased from $111.5 million at the end of 2023 to $61.7 million as of June 30, 2024, raising concerns about long-term financial sustainability.
- The company has not yet met with the FDA regarding recent enrollment data for its UPS study, indicating potential delays in regulatory progress.
- BioAtla Inc (BCAB) is not currently enrolling new patients in certain programs, which may slow down the pace of clinical development.
Good day, everyone. And welcome to todayâs BioAtla second quarter 2024 earnings call. (Operator Instructions)
It is now my pleasure to turn the conference over to Bruce Mackle of LifeSci Advisors.
Thank you, Operator, and good afternoon, everyone. With me today on the phone from BioAtla are Dr. Jay Short, Chairman, CEO and Co-Founder; and Richard Waldron, Chief Financial Officer. Following todayâs call, Dr. Eric Sievers, Chief Medical Officer; and Sheri Lydick, Chief Commercial Officer, will join Jay and Eric in a short Q&A.
Earlier this afternoon, BioAtla released financial results and a business update for the second quarter ended June 30, 2024. A copy of the press release and corporate presentation are available on the companyâs website.
Before we begin, Iâd like to remind everyone that statements made during this conference call will include forward-looking statements, including, but not limited to, statements regarding BioAtlaâs business plans and prospects and whether its
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
